ETFsNASDAQ Biotechnology NET Index
iShares

iShares Nasdaq US Biotechnology UCITS ETF

2B70 XETRAAccumulatingPhysical, full replicationIreland
Last close · EUR
9.44EUR
-1.15% · -€0.11
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
2B70Base
Fund charges
Not publishedFee basis unverified
Fund size
Not published
Return 1Y
+40.7%
Sharpe 3Y
0.95
Volatility 1Y
19.2%annualised
Holdings
240Fund holdings

Performance

Compare
  • 2B70+40.7%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
2B70+4.4%+13.2%+28.8%+32.0%+40.7%+80.2%+53.7%
MSCI World-2.8%-0.6%+7.8%+14.0%+14.1%+65.6%+64.8%
Gap to MSCI World+7.3%+13.8%+21.0%+18.0%+26.6%+14.5%-11.1%

Risk and return

Sharpe ratio · 3Y
0.95
Below MSCI World · 1.24
Return p.a.
+22.3%
Volatility
20.3%
Max loss
-29.4%Apr 2025

Sharpe vs indices

MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
2B70
0.95
MSCI Emerging Markets IMI
0.93
CAC 40
0.37
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
48.3%
Holdings
240
As of
Fund holdings
  1. 1GILEAD SCIENCES9.10%
  2. 2AMGEN INC8.47%
  3. 3VERTEX PHARMACEUTICALS7.68%
  4. 4MODERNA6.44%
  5. 5REGENERON PHARMACEUTICALS5.87%
  6. 6REVOLUTION MEDICINES2.67%
  7. 7BIOGEN2.35%
  8. 8ILLUMINA INC2.13%
  9. 9ROYALTY PHARMA PLC CLASS A1.88%
  10. 10ROIVANT SCIENCES LTD1.72%

Countries

Classified 5.6%
Largest
1.6%Belgium
Top 3
3.6%
Effective number
1,873.21 / HHI

Market cap

Weight vs holdings

48.3%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-50
  • Holdings 51-200
  • Holdings 201+

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.